HCW Biologics Reports Second Quarter 2026 Business and Clinical Development Highlights and Financial Results
HCW Biologics Inc. reported Q2 2026 financial results showing increased revenues mainly from licensing agreements, detailed preliminary human data from its Phase 1 clinical trial of HCW9302 for alopecia areata, reacquisition of ex vivo rights for commercial-ready molecules, and ongoing development efforts for a T-cell engager for solid tumors. The …